Adam B Polis
Overview
Explore the profile of Adam B Polis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Farnier M, Guyton J, Jensen E, Polis A, Johnson-Levonas A, Brudi P
Atherosclerosis
. 2013 Jul;
229(2):415-22.
PMID: 23880197
Background/synopsis: Apolipoprotein (apo) B is highly predictive of coronary risk, especially in patients with high triglycerides (TG). This post hoc analysis evaluated the effects of lipid-lowering therapy on correlations between...
12.
Lauring B, Taggart A, Tata J, Dunbar R, Caro L, Cheng K, et al.
Sci Transl Med
. 2012 Aug;
4(148):148ra115.
PMID: 22914621
Nicotinic acid (niacin) induces beneficial changes in serum lipoproteins and has been associated with beneficial cardiovascular effects. Niacin reduces low-density lipoprotein, increases high-density lipoprotein, and decreases triglycerides. It is well...
13.
Fazio S, Guyton J, Polis A, Adewale A, Tomassini J, Ryan N, et al.
Am J Cardiol
. 2010 Feb;
105(4):487-94.
PMID: 20152243
The safety and efficacy of combination ezetimibe/simvastatin (E/S) plus extended-release niacin was assessed in 942 patients with type IIa/IIb hyperlipidemia for 64 weeks in a randomized, double-blind study. Patients received...
14.
Goldberg R, Guyton J, Mazzone T, Weinstock R, Polis A, Tipping D, et al.
Diabetes Care
. 2010 Feb;
33(5):1021-4.
PMID: 20150290
Objective: To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes. Research Design: AND METHODS Multivariable analyses of treatment response in 1,229 type 2 diabetic patients...
15.
Polis A, Abate N, Catapano A, Ballantyne C, Davidson M, Smugar S, et al.
Metab Syndr Relat Disord
. 2009 Nov;
7(6):601-10.
PMID: 19929597
Background: Patients with diabetes mellitus (DM) and metabolic syndrome are at increased risk of coronary heart disease (CHD). Studies have shown differential statin efficacy on low-density lipid cholesterol (LDL-C) by...
16.
Lipsky B, Polis A, Lantz K, Norquist J, Abramson M
Wound Repair Regen
. 2009 Aug;
17(5):671-7.
PMID: 19671126
Scoring the severity of a diabetic foot wound infection may help assess the severity, determine the type and urgency of antibiotic and surgical treatment needed, and predict clinical outcomes. We...
17.
Robinson J, Ballantyne C, Grundy S, Hsueh W, Parving H, Rosen J, et al.
Am J Cardiol
. 2009 Jun;
103(12):1694-702.
PMID: 19539078
Patients with the metabolic syndrome are at an increased risk of cardiovascular disease and might require intensive lipid therapy. Many patients remain at the starting dose of lipid therapy and...
18.
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial
Lipsky B, Sheehan P, Armstrong D, Tice A, Polis A, Abramson M
Int Wound J
. 2007 Apr;
4(1):30-8.
PMID: 17425547
To aid clinicians in selecting the appropriate approach for treating patients with diabetic foot infections, we investigated whether any baseline clinical findings predicted an unfavourable clinical outcome. Using data from...
19.
Armstrong D, Lipsky B, Polis A, Abramson M
Int Wound J
. 2007 Jan;
3(4):302-7.
PMID: 17199766
The purpose of the study was to assess in patients with a diabetic foot infection (DFI), whether differences in skin temperature of the affected foot as compared to the corresponding...
20.
Smugar S, Schnitzer T, Weaver A, Rubin B, Polis A, Tershakovec A
Curr Med Res Opin
. 2006 Jul;
22(7):1353-67.
PMID: 16834834
Objective: To compare the efficacy of rofecoxib and celecoxib for the treatment of knee or hip OA over 6 weeks. Methods: Two similarly designed, multicenter, randomized, double-blind, placebo-controlled studies. Patients...